Merck (MRK) hikes outlook for 2024 as Q1 print beats analyst estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Merck (MRK) Tops Q1 EPS by 14c, Beats on Revenue; Offers FY24 Guidance
April 25, 2024 6:33 AM EDTMerck (NYSE: MRK) reported Q1 EPS of $2.07, $0.14 better than the analyst estimate of $1.93. Revenue for the quarter came in at $15.8 billion versus the consensus estimate of $15.22 billion.
GUIDANCE:
Merck sees FY2024 EPS of $8.53-$8.65, versus the consensus of $8.56. Merck sees... More
